when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

OTSUKA · news · pharmadog

← back to OTSUKA

News mentioning OTSUKA

30 stories

19hOtsuka succeeds with kidney drug; BioNTech downgrades revenue projectionendpoints

23hVertex unfazed by competitive IgAN space as FDA verdict loomsbiospace

7dEli Lilly tops new biopharma ranking on launch success, development speedfiercebiotech

8dYarrow to begin trading as it targets Graves; FDA approves Otsuka's ADHD pillendpoints

8dFDA scientists question Capricor data; Legend CEO steps downbiopharma dive

8dOtsuka’s ADHD approval opens up new drug class with $615M opportunitybiospace

11dLilly’s $3.8B psychedelics bet won’t open the M&A floodgatesbiospace

15dLilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelicsbiospace

18d‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelicsfiercebiotech

19dLilly to buy AtaiBeckley for $2.8B, further validating psychedelicsbiopharma dive

28dVera's IgAN approval kicks off competition with Otsukaendpoints

28dVera Therapeutics wins FDA nod for closely watched kidney disease drugbiopharma dive

29dRoche aims to bolster breast cancer pipeline with early-stage Astex dealendpoints

Jul 2, 26Otsuka reports long-term kidney data key to Voyxact's bid for full approvalendpoints

Jul 1, 26BridgeBio gets funding for drug launch; United buys into cell therapybiopharma dive

Jun 29, 2610 clinical trials to watch in the second half of 2026biopharma dive

Jun 26, 26FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences servicesbiopharma dive

Jun 8, 26Opinion: $2 million gene therapy cures require a financing modelstat

Jun 6, 26STAT+: Lilly shares safety, tolerability data on its next-gen obesity drugstat

Jun 6, 26STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potentialstat

Jun 5, 26STAT+: Will Makary’s FDA voucher program survive?stat

Jun 5, 26Texas AG investigating energy drinksstat

Jun 4, 26HHS confirms Americans with high-risk Ebola exposures will have access to experimental therapystat

Jun 4, 26Otsuka touts new IgAN evidence as it seeks full approval for Voyxactendpoints

Jun 4, 26STAT+: Drug companies, patient groups urge FDA to pause commissioner’s voucher programstat

Jun 4, 26STAT+: Otsuka kidney drug slowed loss of function, but less than expected, in late-stage trialstat

Jun 4, 26Otsuka showcases kidney drug data; Pfizer cuts an AI dealbiopharma dive

May 7, 26Angelini to buy Catalyst in $4B play for rare neuro drugsbiopharma dive

May 6, 26Opinion: Trump’s executive order on psychedelics is the right move. But is my field ready for it?stat

Dec 22, 25Fierce Biotech Fundraising Tracker '26: Ratio rounds up $70M; Crystalys culls $130Mfiercebiotech